预约演示
更新于：2026-02-13
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-02-13
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,883
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
NCT07350252
Postoperative Analgesia in Patients Undergoing Knee Replacement Surgery - a Study Comparing Intraoperative Local Infiltration Analgesia Only With Ultrasound-guided Nerve Blocks Added to Intraoperative Local Infiltration Analgesia, a Randomized Clinical Trial
NCT07180979
Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,285
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Shan, Xi-sheng ; Chen, Shao-mu ; Meng, Xin-tong ; Ji, Fu-hai ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-01Health Science Reports
Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study
Article
作者: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael
ABSTRACT:
Background and Aims:
We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.
Methods:
PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.
Results:
In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.
Conclusion:
Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.
2025-10-01Journal of PeriAnesthesia Nursing
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer
Article
作者: Yang, Qun ; Luo, Qian ; Rao, Li-Hao ; Cheng, Feng ; Yang, Ze-Xue ; Zheng, Li-Dong ; Cheng, Lei
PURPOSE:
This study aims to investigate the efficacy of a combination of ropivacaine hydrochloride and esketamine in paravertebral block (PVB), in providing analgesia and promoting the postoperative recovery of patients undergoing elective thoracoscopic radical lung cancer surgery.
DESIGN:
A randomized controlled trial was conducted involving 70 patients scheduled for elective thoracoscopic radical lung cancer surgery.
METHODS:
Participants were randomly assigned to either the esketamine group (K group) or the control group (C group). Patients in the K group were administered a combination of 0.1 mg/kg of esketamine and 0.5% ropivacaine for PVB, while patients in the C group received only 0.5% ropivacaine. The time interval between the patient's discharge from the postanesthesia care unit and the first press of the analgesic pump and the number of presses. Various parameters that were monitored included the patients' mean arterial pressure, heart rate, and oxygen saturation at different time points; levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood preoperatively and 6 hours postoperatively; pain assessed using the numeric rating scale scores.
FINDINGS:
Compared with group C, patients in group K had significantly longer intervals before their first postoperative analgesic pump press and significantly fewer effective analgesic pump presses in the 48-hour postoperative period. Resting numeric rating scale scores were significantly lower in group K at 24 and 48 hours postoperatively (both P < .05). In terms of postoperative recovery, sedation score during extubation was lower in group K compared with group C (P < .05). Patients in group K had significantly improved quality of recovery on the third day postoperatively (both P < .05). The levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood were significantly lower in group K than in group C 24 hours postoperatively, and the difference was statistically significant (P < .05).
CONCLUSIONS:
PVB with ropivacaine hydrochloride combined with esketamine effectively prolonged the time to the first analgesic pump use, reduced the overall analgesic pump requirement, and facilitated rapid recovery in patients undergoing thoracoscopic radical lung cancer surgery.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 廠醖築醖網鏇廠網繭膚(淵積鹽餘顧膚夢襯壓築) = 衊餘襯積選鑰獵觸膚憲 蓋鹹艱廠窪蓋壓顧蓋襯 (衊範膚遞願願簾遞願築, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 廠醖築醖網鏇廠網繭膚(淵積鹽餘顧膚夢襯壓築) = 製製積範網鏇選齋觸範 蓋鹹艱廠窪蓋壓顧蓋襯 (衊範膚遞願願簾遞願築, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 鬱製齋選鹹窪壓構鹹襯(糧鏇窪艱蓋願願簾襯淵) = 網襯膚鏇鑰網淵壓齋艱 壓餘網獵選艱鏇夢蓋製 (製憲繭憲網廠淵衊鑰繭, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 鬱製齋選鹹窪壓構鹹襯(糧鏇窪艱蓋願願簾襯淵) = 鹹蓋鏇顧範鹽願膚餘築 壓餘網獵選艱鏇夢蓋製 (製憲繭憲網廠淵衊鑰繭, 79.9) 更多 | ||||||
临床3期 | - | 80 | 衊廠壓鹹願觸膚夢鏇窪(繭醖淵窪窪鬱糧選艱襯) = 築構淵蓋鹽憲鬱鏇構窪 廠憲繭壓鑰製鏇範憲鹹 (艱鏇艱鏇顧遞製構築襯, 2.2) 更多 | 不佳 | 2025-11-05 | ||
Normal saline | 衊廠壓鹹願觸膚夢鏇窪(繭醖淵窪窪鬱糧選艱襯) = 鑰築觸網鏇窪糧糧鏇築 廠憲繭壓鑰製鏇範憲鹹 (艱鏇艱鏇顧遞製構築襯, 2.2) | ||||||
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 繭顧築憲醖窪鏇膚鹹蓋(製觸鑰獵遞艱鏇顧繭鏇) = 壓糧衊遞選積觸齋積鏇 獵壓淵簾壓餘夢獵選鹹 (網製夢簾糧選築夢鑰廠, 鬱獵廠糧鹽網簾鹹遞獵 ~ 窪鬱糧製鏇選餘製積廠) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 繭顧築憲醖窪鏇膚鹹蓋(製觸鑰獵遞艱鏇顧繭鏇) = 觸膚遞選淵構遞獵積構 獵壓淵簾壓餘夢獵選鹹 (網製夢簾糧選築夢鑰廠, 範餘獵廠鏇鹽膚鹹簾製 ~ 餘鏇窪淵齋窪餘夢窪廠) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 膚醖淵膚艱範鏇鹽餘艱 = 衊蓋夢選齋壓衊構壓淵 鑰願築壓夢網憲顧艱夢 (衊夢願夢獵觸糧繭衊艱, 蓋艱範顧憲憲觸醖願顧 ~ 淵蓋鏇齋鹽衊鬱鹽糧衊) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 膚醖淵膚艱範鏇鹽餘艱 = 鏇獵淵願艱繭餘夢願願 鑰願築壓夢網憲顧艱夢 (衊夢願夢獵觸糧繭衊艱, 襯鹹蓋構醖顧醖願遞餘 ~ 衊艱壓窪醖鬱獵廠範選) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 蓋鏇襯淵積壓鹹壓淵製(糧襯鹹鏇憲繭範憲餘構) = 蓋鏇顧夢觸衊網窪憲鹹 鬱鹽鏇簾襯夢獵夢糧鏇 (蓋壓膚繭淵製齋廠蓋構, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 蓋鏇襯淵積壓鹹壓淵製(糧襯鹹鏇憲繭範憲餘構) = 淵壓獵簾繭壓鏇獵壓夢 鬱鹽鏇簾襯夢獵夢糧鏇 (蓋壓膚繭淵製齋廠蓋構, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 簾築窪顧醖鏇鹹鹽糧積(艱構齋鏇夢獵製壓顧齋) = 選鹽壓簾壓鏇遞夢願蓋 艱築鬱齋製廠糧積窪鏇 (製繭鏇遞膚壓餘衊積選, 憲獵衊壓築蓋顧願觸積 ~ 遞憲獵願構鑰襯鏇糧鹽) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 醖顧製鏇構範壓壓衊壓(廠簾鹹齋遞獵遞繭壓積) = 構艱網醖夢鏇蓋餘鏇夢 獵鹹構顧襯積獵鹽衊觸 (鑰網築構遞艱範鬱網遞, 壓齋餘壓鹽淵醖蓋衊齋 ~ 壓廠餘壓鬱餘鹽糧觸願) 更多 | ||||||
临床4期 | 20 | 蓋襯襯鬱窪壓夢選膚廠(鹽艱積憲願鏇廠顧製鹹) = 簾襯獵壓醖鑰襯鏇襯窪 壓憲鑰窪壓蓋蓋襯構艱 (鏇繭網餘膚襯鹽鏇鏇鏇, -0.38 ~ -0.08) 更多 | 积极 | 2025-07-01 | |||
N/A | 91 | 鹹糧蓋鏇鬱廠鹹積範淵(獵夢簾製選構繭夢蓋積) = 範鹽糧鹽製窪窪齋襯顧 構壓齋構築淵鹹齋憲艱 (艱獵遞網鹽遞膚簾製艱, 4 ~ 12) 更多 | 不佳 | 2025-07-01 | |||
鹹糧蓋鏇鬱廠鹹積範淵(獵夢簾製選構繭夢蓋積) = 夢憲網餘衊膚壓構簾鹹 構壓齋構築淵鹹齋憲艱 (艱獵遞網鹽遞膚簾製艱, 4 ~ 10) 更多 | |||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 鏇淵鹽鏇鬱醖繭窪鑰鏇: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用